# Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

> **NCT00875524** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 180 (actual)

## Conditions studied

- Dengue Virus
- Dengue Fever
- Dengue Hemorrhagic Fever
- Dengue Disease

## Interventions

- **BIOLOGICAL:** CYD dengue vaccine serotypes (1, 2, 3, 4).
- **BIOLOGICAL:** Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide

## Key facts

- **NCT ID:** NCT00875524
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2014-08
- **Final completion:** 2014-12
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00875524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00875524, "Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00875524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*